# Armistice Capital

> Armistice Capital is a VC fund backing Biotechnology, Health Care and Pharmaceutical. See 27 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 27
- Last investment: May 2026
- Lead investor: 26%
- Last updated: Aug 2026

Armistice Capital is a global, value-oriented and event-driven hedge fund focused primarily on the health care and consumer sector.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 89% |
| Health Care | 14 | 52% |
| Pharmaceutical | 11 | 41% |
| Therapeutics | 10 | 37% |
| Medical | 8 | 30% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 26 | 96% |
| Post-IPO Debt | 1 | 4% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 20 | 74% |
| France | 3 | 11% |
| Canada | 1 | 4% |
| Israel | 1 | 4% |
| Germany | 1 | 4% |

6 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rapid Micro Biosystems | Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $32M | Post-IPO Equity | May 19, 2026 |  |
| Adocia | Adocia operates as a biotechnology company specializing in tissue regeneration. Adocia was founded in 2005 as Proteins & Peptides Management S.A.S. and changed its name to Adocia in January 2008. Adocia is based in Lyons, France. | $10.2M | Post-IPO Equity | Feb 26, 2025 |  |
| ProMIS Neurosciences | ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).It was founded in 2004 and headquartered in Toronto,Canada. | $30.3M | Post-IPO Equity | Jul 26, 2024 |  |
| Assembly Biosciences | Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome.Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. | $12.6M | Post-IPO Equity | Jun 17, 2024 |  |
| Corvus Pharmaceuticals | Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology. | $30.6M | Post-IPO Equity | May 02, 2024 |  |
| Zura Bio | Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 development programs, such as ZB-168 and torudokimab, with auto-immune illnesses. ZB-168 is an anti-IL7R inhibitor that may have an effect on disorders whose biological pathways are IL7 and TSLP. They create therapeutic indications for ZB-168 that build on thetype 1 diabetes data from Phase 1b studies and show a profile and biological basis. The phase 2 clinical development stage of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33, has been established. | $112.5M | Post-IPO Equity | Apr 18, 2024 |  |
| Protara Therapeutics | Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipidsubstrate replacement therapy for the treatment of intestinal failure-associated liver disease.The Protara team prioritizes creativity, diverse perspectives, and tenacity to expedite their goal of bringing life-changing therapies to people with limited treatment options. | $45M | Post-IPO Equity | Apr 05, 2024 |  |
| CervoMed | CervoMed is a clinical-stage firm devoted to the research and commercialization of therapeutic treatments for neurodegenerative illnesses, with an emphasis on the early phases of the disease's progression. | $149.4M | Post-IPO Debt | Mar 28, 2024 |  |
| Vulcan Infrastructure | Greenidge is a 106MW natural gas power plant and blockchain mining facility. Greenidge Generation has been transformed into a power plant for the twenty-first century. In January 2020, Greenidge launched the first phase of a data center for blockchain mining. Greenidge was established in 1937 and is based in Dresden, New York, United States. | $6M | Post-IPO Equity | Feb 12, 2024 |  |
| Tenaya Therapeutics | Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration,enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies. | $50M | Post-IPO Equity | Feb 08, 2024 |  |

10 of 27 investments shown.

## Co-investors
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 5 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 5 deals together
- [Nantahala Capital Management](https://shizune.co/investors/profile/nantahala-capital-management) — VC Fund, 4 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 3 deals together
- Great Point Partners — VC Fund, 3 deals together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Armistice Capital invest in?

Armistice Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Post-IPO Debt stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Armistice Capital last invest?

The most recent investment recorded for Armistice Capital closed in May 2026. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co